Press Releases concerning clinical trial results are intended to inform interested parties of the advancements of laser technology in process, not to imply new indications for use. Erchonia supports only those indications for use, cleared by the FDA via 510(k).
Erchonia Receives 7th FDA Market Clearance for Non Invasive Fat Loss
Patent no. US 8, 932,338B2- a noninvasive method of reducing fat from targeted regions of a patient's body by applying low-level laser energy externally through the skin of the patient to the targeted areas. The laser works by applying sufficient energy to release intracellular fat into the interstitial space. The released intra-cellular fat is removed through the body's natural functions.
McKinney, TX (PRWEB) April 22, 2014
Erchonia today announces that the preliminary results of an ongoing clinical trial testing its Lunula laser for the noninvasive treatment of nail fungus have been published in the latest issue of the medical journal Podiatry Review.